Clinical Trials Browser

Phase 1/2 × Disease × Nivolumab × Clear all

NCT06767956 2025-06-04

Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell Therapy

Phase 1/2 Not yet recruiting

Disease, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell